IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Intravenous Vitamin C in the Treatment of Viral Infection, Especially in the Treatment of Shingles (168)
This study has been completed.
Sponsor:
Pascoe Pharmazeutische Praeparate GmbH
Collaborator:
Dr. Loges & Co. GmbH
Information provided by (Responsible Party):
Pascoe Pharmazeutische Praeparate GmbH
ClinicalTrials.gov Identifier:
NCT00921934
First received: June 16, 2009
Last updated: September 25, 2012
Last verified: August 2012
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
Chronic viral infections induce oxidative stress that can cause a number of concomitant diseases, e.g. cardio-vascular diseases or metabolic disorders. Therefore, a sufficient treatment of oxidative stress may be of benefit for the patient to prevent further diseases.
Shingles (herpes zoster infection) have been successfully treated with antioxidative substances like high-dose vitamin C for ages. Not only the acute symptoms can be diminished by high-dose vitamin C. Even long-term sequelae, like painful post-herpetic neuropathy, may be mitigated or even fully avoided.
| Condition |
|---|
| Virus Diseases Herpes Zoster |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | PASCORBIN 7.5g in the Treatment of Viral Infection, Especially Varicella Zoster Infection: An Observational Cohort Study |
Resource links provided by NLM:
Further study details as provided by Pascoe Pharmazeutische Praeparate GmbH:
Primary Outcome Measures:
- Change of Pain Measured by VAS [ Time Frame: visit 1 - 3 ]VAS (minimum = 0 = no pain, maximum = 10 = extrem pain, change of pain measured by VAS
| Enrollment: | 68 |
| Study Start Date: | April 2009 |
| Study Completion Date: | December 2010 |
| Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
Vitamin C
Adult patients suffering from acute viral infection, especially herpes zoster, presenting themselves in Primary Care Centers or hospitals all over Germany, and who are treated with standard therapy and add-on vitamin C.
|
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Cohort of adult patients suffering from acute viral infections, especially herpes zoster, presenting themselves in Primary Care Centers or hospitals all over Germany.
Criteria
Due to the design of an Observational Cohort Study, no inclusion or exclusion criteria are named. The included patient group is described under "Cohort / Group".
Observational Criteria:
- adult patients
- acute viral infection (especially herpes zoster)
- Primary Care patient
- eligible for add-on therapy with vitamin C
- willingness to provide pseudonymized data to the Sponsor
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00921934
Please refer to this study by its ClinicalTrials.gov identifier: NCT00921934
Locations
| Germany | |
| Praxis Dr. Schencking, Rheinstr. 77a | |
| Ransbach-Baumbach, Rheinland-Pfalz, Germany, 56235 | |
Sponsors and Collaborators
Pascoe Pharmazeutische Praeparate GmbH
Dr. Loges & Co. GmbH
Investigators
| Principal Investigator: | Martin Schencking, MD | Rheinstr. 77a, D-56235 Ransbach-Baumbach |
| Study Director: | Bianka Krick | Pascoe Pharmazeutische Praeparate GmbH |
More Information
| Responsible Party: | Pascoe Pharmazeutische Praeparate GmbH |
| ClinicalTrials.gov Identifier: | NCT00921934 History of Changes |
| Other Study ID Numbers: |
168 A 08 VC |
| Study First Received: | June 16, 2009 |
| Results First Received: | August 1, 2012 |
| Last Updated: | September 25, 2012 |
Keywords provided by Pascoe Pharmazeutische Praeparate GmbH:
|
Herpes Shingles virus disease vitamin C |
ascorbic acid antioxidant oxidative stress |
Additional relevant MeSH terms:
|
Herpes Zoster Virus Diseases Herpesviridae Infections DNA Virus Infections Vitamins Ascorbic Acid |
Micronutrients Growth Substances Physiological Effects of Drugs Antioxidants Molecular Mechanisms of Pharmacological Action Protective Agents |
ClinicalTrials.gov processed this record on June 23, 2017